C
Colin Zhang
Researcher at Incyte
Publications - 49
Citations - 947
Colin Zhang is an academic researcher from Incyte. The author has contributed to research in topics: Pyrazine & Cancer. The author has an hindex of 14, co-authored 46 publications receiving 911 citations.
Papers
More filters
Journal ArticleDOI
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
Phillip Liu,Xiangdong Liu,Yanlong Li,Maryanne B. Covington,Richard Wynn,Reid Huber,M.C. Hillman,Gengjie Yang,Dawn Ellis,Cindy Marando,Kamna Katiyar,Jodi D. Bradley,Kenneth Abremski,Mark Stow,Mark Rupar,Jincong Zhuo,Yun-Long Li,Qiyan Lin,David M. Burns,Meizhong Xu,Colin Zhang,Ding-Quan Qian,Chunhong He,Vaqar Sharief,Lingkai Weng,Costas Agrios,Eric Shi,Brian Metcalf,Robert Newton,Steven M. Friedman,Wenqing Yao,Peggy A. Scherle,Gregory F. Hollis,Timothy Burn +33 more
TL;DR: In vitro studies demonstrate that in combination with low doses of Herceptin, selective ADAM 10 inhibitors decrease proliferation in HER2 overexpressing cell lines while inhibitors, that do not inhibit ADAM10, have no impact.
Patent
Amido compounds and their use as pharmaceuticals
TL;DR: In this article, the authors proposed a method for the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases related with aldosterone excess.
Patent
Imidazotriazines and imidazopyrimidines as kinase inhibitors
Jincong Zhuo,Brian W. Metcalf,Meizhong Xu,Chunhong He,Colin Zhang,Ding-Quan Qian,David M. Burns,Li Yun-Long,Wenqing Yao +8 more
TL;DR: In this article, the present invention is directed to imidazo[1,2-b][1 2,4]triazines and imidaze[1 2,2,4]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Patent
N-substituted piperidines and their use as pharmaceuticals
TL;DR: In this paper, the authors present an invention related to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof.
Patent
Lactam compounds and their use as pharmaceuticals
Wenqing Yao,Chunhong He,Jincong Zhuo,Meizhong Xu,Colin Zhang,Ding-Quan Qian,David M. Burns,Brian Metcalf +7 more
TL;DR: In this paper, the authors proposed a method for the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases related with aldosterone excess.